Neo-adjuvant STI571 therapy for high-risk gastrointestinal stromal tumour [6]

ANZ Journal of Surgery

Volumn 74, Issue 4, 2004, Pages 289-290

  Liu, Chien Liang ^a   Huang, Ming Jer ^a   Lin, Shee Chan ^a   Chang, Kuo Ming ^a   Tzen, Chin Yuan ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ADJUVANT CHEMOTHERAPY; AGED; CANCER SURGERY; CASE REPORT; CODON; COMPUTER ASSISTED TOMOGRAPHY; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; LETTER; MALE; NEEDLE BIOPSY; PATIENT REFERRAL; POSTOPERATIVE PERIOD; TUMOR VOLUME;

EID: 2442626666     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2004.02973.x     Document Type: Letter

References (4)

1. Huilgol R, Young CJ, Solomon MJ. The GIST of it: case reports of a gastrointestinal stromal tumour and a leiomyoma of the anorectum. ANZ J. Surg. 2003; 73: 167-9.
2. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastasis gastrointestinal stromal tumor. N. Engl. J. Med. 2001; 344: 1052-6.
3. DeMatteo RP. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann. Surg. Oncol. 2002; 9: 831-9.
4. Singer S, Rubin BP, Lux MI et al. Prognostic value of kit mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol. 2002; 20: 3898-905.